Onyx rejects Amgen's takeover bid

  @emilyjanefox June 30, 2013: 2:36 PM ET
NEW YORK (CNNMoney)

Onyx Pharmaceuticals has rejected a takeover bid by biotechnology company Amgen.

Onyx (ONXX), which develops cancer drugs and treatments, said Monday that Amgen's takeover bid of $120 a share undervalued the company. Onyx stock closed Friday at $86.82.

"We are actively exploring the potential to combine Onyx with another company as an option to create additional value for Onyx shareholders," said Onyx CEO N. Anthony Coles.

Related: Brutal June clouds stocks outlook for 2nd half

Shares of Onyx rose more than 6% last week on news of Amgen's offer. Overall, the stock has increased nearly 36% since last year.

Amgen (AMGN, Fortune 500) is a major player in biopharmaceuticals, and manufactures drugs for many conditions, including ones that counteract the effects of cancer treatments. To top of page



Join the Conversation
CNNMoney Sponsors
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.